Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Change in Acquisitions & Divestments (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $27.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Change in Acquisitions & Divestments changed N/A year-over-year to $27.5 million, compared with a TTM value of $64.5 million through Dec 2024, up 1811.11%, and an annual FY2024 reading of $64.5 million, up 1811.11% over the prior year.
  • Change in Acquisitions & Divestments was $27.5 million for Q4 2024 at Oramed Pharmaceuticals, up from $2.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $27.5 million in Q4 2024 and bottomed at -$1.8 million in Q2 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $6.8 million, with a median of $2.0 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments tumbled 228.62% in 2023, then surged 1226.76% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $1.5 million in 2022, then plummeted by 58.06% to $650000.0 in 2023, then skyrocketed by 4130.77% to $27.5 million in 2024.
  • Business Quant data shows Change in Acquisitions & Divestments for ORMP at $27.5 million in Q4 2024, $2.0 million in Q3 2024, and $20.0 million in Q2 2024.